Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 13/20 | 0.54 |
| ▸ | CCND1 | P24385 | 9/20 | 0.54 |
| ▸ | CDK2 | P24941 | 8/20 | 0.54 |
| ▸ | CCND3 | P30281 | 8/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.54 |
| ▸ | CDK9 | P50750 | 4/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 3/20 | 0.49 |
| ▸ | CCNH | P51946 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | CCND2 | P30279 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246773 | 0.83 | CDK4 (0.62) | CDK4CDK6CCND1CDK2CCND3 | |
| SCHEMBL4247804 | 0.83 | CDK4 (0.62) | CDK4CDK6CCND1CDK2CCND3 | |
| SCHEMBL3549927 | 0.79 | CDK4 (0.61) | CDK4CDK6CCND1CDK2CCND3 | |
| SCHEMBL3548645 | 0.77 | CDK2 (0.80) | CDK2KCNH2CDK1 | |
| SCHEMBL5239921 | 0.77 | CDK2 (0.80) | CDK2KCNH2CDK1 | |
| SCHEMBL3553510 | 0.77 | CDK2 (0.80) | CDK2KCNH2CDK1 | |
| SCHEMBL4254074 | 0.74 | CDK2 (0.81) | CDK4CDK6CCND1CDK2CCND3 | |
| SCHEMBL4254071 | 0.74 | CDK2 (0.81) | CDK4CDK6CCND1CDK2CCND3 | |
| SCHEMBL4408142 | 0.72 | CDK6 (0.59) | CDK4CDK6CCND1CDK2CDK1 | |
| SCHEMBL3554221 | 0.72 | CDK2 (0.70) | CDK4CDK6CCND1CDK2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | MKI67, TYMP, PCNA | CDK4 30/4885CDK6 60/4885CCND1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.